

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	6285044
<b>Application Number:</b>	10539385
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	4857
<b>Title of Invention:</b>	BENZAEPINE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
<b>First Named Inventor/Applicant Name:</b>	Sanjeet Sehmi
<b>Customer Number:</b>	23347
<b>Filer:</b>	Duke M. Fitch/Mary Fenerty
<b>Filer Authorized By:</b>	Duke M. Fitch
<b>Attorney Docket Number:</b>	P33159USW
<b>Receipt Date:</b>	19-OCT-2009
<b>Filing Date:</b>	16-JUN-2005
<b>Time Stamp:</b>	14:43:13
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$810
RAM confirmation Number	807
Deposit Account	192570
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Request for Continued Examination (RCE)	RCE_Transmittal.pdf	95164 cc916da110044d31e26d7266401e1c184884	no	1
Warnings:					
This is not a USPTO supplied RCE SB30 form.					
Information:					
2		Information_Disclosure_State ment_and_1449.pdf	263722 4a1308d6c6f09ab4c08a7b97266401e1c2763708	yes	3
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	1	
	Information Disclosure Statement (IDS) Filed (SB/08)		2	3	
Warnings:					
Information:					
3	Foreign Reference	1WO9605194A1.pdf	5789360 c539745f8403c9070a204dd81fa7a009afadcd	no	154
Warnings:					
Information:					
4	Foreign Reference	2WO2004058682A1_part_1.pdf	16171064 a5291e89ba0127d6d7de57268153f3dec2da9ba	no	491
Warnings:					
Information:					
5	Foreign Reference	2WO2004058682A1_part_2.pdf	12668023 8a9829559153b244a6a192d2b11ad407e3c5d996	no	491
Warnings:					
Information:					
6	Foreign Reference	3WO2005014479A2.pdf	1168787 f7959c1e838b782774830059e5f80b3e6d1d26af	no	28
Warnings:					
Information:					

7	Foreign Reference	4WO2005039591A1.pdf	2113209 64443b6dc3a417a15afcc00213f6295f6bfc	no	43
<b>Warnings:</b>					
<b>Information:</b>					
8	Foreign Reference	5WO2005058328A1.pdf	2938402 89f1c61995ced6d736d49812d5598ebc3c7f0476	no	66
<b>Warnings:</b>					
<b>Information:</b>					
9	Foreign Reference	6CA2197789.pdf	5373828 7cc06d5efb199d879e6fc5b48b536cax02c8b	no	151
<b>Warnings:</b>					
<b>Information:</b>					
10	Foreign Reference	7EP0612741B1.pdf	3860319 2aeb6dc07268b12d1fca0f6e7ba3dbed89714fa	no	95
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	8Medhurst_BiochemPharmacol_2007.pdf	592134 89fc11919bdc4133c6372028b4798ebd3afcd09	no	13
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	9Southam_Psychoph_2009.pdf	286856 d517b70193c28c38c316dc5e0961881354cd7b	no	12
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	10Medhurst_JPharmExpTher_2007.pdf	570693 af52a6de3fa183b799dcf717baa3db62245203bb	no	14
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	11Medhurst_Pain_2008.pdf	411907 f713cd4fb18cf5d8f5c1e45a25f7a7276c637b	no	9
<b>Warnings:</b>					
<b>Information:</b>					
15	NPL Documents	12Perez-Garcia_Psychopharmacology_1999.pdf	113685 829acfe9ebf7c9f3c636b6d608a63c9c2abacdf	no	6
<b>Warnings:</b>					
<b>Information:</b>					

16	NPL Documents	13Fox_JPharmExpTher_2005.pdf	918938 2177686233c9c9a0a2a26075422c02a9c7	no	15
<b>Warnings:</b>					
<b>Information:</b>					
17	NPL Documents	14Wijtmans_ExpOpinionInvestDrugs_2007.pdf	325360 6e6f7361c4906286a377982f817936c9f6c308	no	20
<b>Warnings:</b>					
<b>Information:</b>					
18	NPL Documents	15Celanire_DDT_2005.pdf	361602 e8078f475c40904275e60901e02ee1d4dc47a70	no	15
<b>Warnings:</b>					
<b>Information:</b>					
19	NPL Documents	16Sander_BioPharmBull_2008.pdf	2446624 b808aa42a2c5e96b82636f144056f17a78f8c11	no	19
<b>Warnings:</b>					
<b>Information:</b>					
20	Fee Worksheet (PTO-875)	fee-info.pdf	30845 761137606946675a69f88b1602123d4ee1a078fcd	no	2
<b>Warnings:</b>					
<b>Information:</b>					
<b>Total Files Size (in bytes):</b>			56500522		

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

#### **New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

#### **National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

#### **New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.